Industry | 2021.06.24
Catalent to Acquire RheinCell Therapeutics, Strengthening a Path Towards Industrialization of Induced Pluripotent Stem Cell-based Therapies
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has reached an agreement to acquire RheinCell Therapeutics GmbH, a developer and manufacturer of GMP-grade human induced pluripotent stem cells (iPSCs). Upon completion, the acquisition will build upon Catalent’s existing custom cell therapy process development and manufacturing capabilities with proprietary GMP cell lines for iPSC-based therapies. The deal will enable Catalent to offer the building blocks to scale iPSC-based cell therapies while reducing barriers to entry to the clinic for therapeutic companies and is expected to close before the end of 2021, subject to customary conditions. Financial details of the transaction have not been disclosed.
(PRWeb June 24, 2021)
Read the full story at https://www.prweb.com/releases/catalent_to_acquire_rheincell_therapeutics_strengthening_a_path_towards_industrialization_of_induced_pluripotent_stem_cell_based_therapies/prweb18028966.htm
For more information, please visit
https://www.prweb.com/releases/catalent_[...]ed_therapies/prweb18028966.htm
